The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Nivolumab-AVD vs brentuximab vedotin-AVD in pediatric patients with cHL: SWOG S1826 trial
Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, discusses the results of the SWOG S1826 trial (NCT03907488), a Phase III study evaluating nivolumab-AVD versus brentuximab vedotin-AVD in patients ≥12 years with advanced stage classical Hodgkin lymphoma (cHL). In this subset analysis of pediatric patients enrolled in the trial, a greater progression-free survival (PFS) was observed in the nivolumab arm, and Dr Friedberg highlights that this treatment regimen is poised to become the standard of care for both adult and pediatric patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
